Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States.

Tremblay, Gabriel; Said, Qayyim; Roy, Anuja Nidumolu; Cai, Beilei; Ashton Garib, Shan; Hearnden, Jaclyn; Forsythe, Anna

Tremblay, Gabriel; Said, Qayyim; Roy, Anuja Nidumolu; Cai, Beilei; Ashton Garib, Shan; Hearnden, Jaclyn; Forsythe, Anna.

Afiliación

Tremblay G; Purple Squirrel Economics, New York, NY, USA.
Said Q; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Roy AN; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Cai B; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Ashton Garib S; Purple Squirrel Economics, New York, NY, USA.
Hearnden J; Purple Squirrel Economics, New York, NY, USA.
Forsythe A; Purple Squirrel Economics, New York, NY, USA.

Clinicoecon Outcomes Res ; 11: 673-681, 2019.

Article en En | MEDLINE | ID: mdl-31814747

Palabras clave

United States; budget impact analysis; costs; eltrombopag; severe aplastic anemia; thrombopoietin receptor agonist

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Clinicoecon Outcomes Res Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google